SEARCH:   Advanced

Blood, 15 August 2005, Vol. 106, No. 4, pp. 1407-1414. Prepublished online as a Blood First Edition Paper on May 5, 2005; DOI 10.1182/blood-2005-03-1080. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-03-1080v1 106/4/1407    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ehrlich, L. A. Articles by Giuliani, N. Search for Related Content PubMed PubMed Citation Articles by Ehrlich, L. A. Articles by Giuliani, N. Related Collections Hematopoiesis and Stem Cells Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma Lori A. Ehrlich, Ho Yeon Chung, Irene Ghobrial, Sun Jin Choi, Francesca Morandi, Simona Colla, Vittorio Rizzoli, G. David Roodman, and Nicola Giuliani From the Department of Medicine, University of Pittsburgh, PA; Veterans Affairs (VA)-Pittsburgh Medical Center, PA; and Cattedra di Ematologia, Universita Degli Studi di Parma, Italy. Bone destruction in multiple myeloma is characterized both by markedly increased osteoclastic bone destruction and severely impaired osteoblast activity. We reported that interleukin-3 (IL-3) levels are increased in bone marrow plasma of myeloma patients compared with healthy controls and that IL-3 stimulates osteoclast formation. However, the effects of IL-3 on osteoblasts are unknown. Therefore, to determine if IL-3 inhibits osteoblast growth and differentiation, we treated primary mouse and human marrow stromal cells with IL-3 and assessed osteoblast differentiation. IL-3 inhibited basal and bone morphogenic protein-2 (BMP-2)-stimulated osteoblast formation in a dose-dependent manner without affecting cell growth. Importantly, marrow plasma from patients with high IL-3 levels inhibited osteoblast differentiation, which could be blocked by anti-IL-3. However, IL-3 did not inhibit osteoblast differentiation of osteoblastlike cell lines. In contrast, IL-3 increased the number of CD45+ hematopoietic cells in stromal-cell cultures. Depletion of the CD45+ cells abolished the inhibitory effects of IL-3 on osteoblasts, and reconstitution of the cultures with CD45+ cells restored the capacity of IL-3 to inhibit osteoblast differentiation. These data suggest that IL-3 plays a dual role in the bone destructive process in myeloma by both stimulating osteoclasts and indirectly inhibiting osteoblast formation. (Blood. 2005;106:1407-1414) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Kukreja, S. Radfar, B.-H. Sun, K. Insogna, and M. V. Dhodapkar Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease Blood, October 15, 2009; 114(16): 3413 - 3421. [Abstract] [Full Text] [PDF] E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Ann. Onc., August 1, 2009; 20(8): 1303 - 1317. [Abstract] [Full Text] [PDF] O. Sezer Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment Oncologist, March 1, 2009; 14(3): 276 - 283. [Abstract] [Full Text] [PDF] F. Silvestris, P. Cafforio, M. De Matteo, N. Calvani, M. A. Frassanito, and F. Dammacco Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells Clin. Cancer Res., October 1, 2008; 14(19): 6081 - 6091. [Abstract] [Full Text] [PDF] J. Kirshner, K. J. Thulien, L. D. Martin, C. Debes Marun, T. Reiman, A. R. Belch, and L. M. Pilarski A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma Blood, October 1, 2008; 112(7): 2935 - 2945. [Abstract] [Full Text] [PDF] J. Lorenzo, M. Horowitz, and Y. Choi Osteoimmunology: Interactions of the Bone and Immune System Endocr. Rev., June 1, 2008; 29(4): 403 - 440. [Abstract] [Full Text] [PDF] Y. Kannan-Hayashi, K. Okamura, S. Hattori, M. Kuwamura, E. Higuchi, H. Terayama, M. Moriyama, M. Mukamoto, M. Okada, Y. Ohsugi, et al. Neuritogenic Effects of T Cell-Derived IL-3 on Mouse Splenic Sympathetic Neurons In Vivo J. Immunol., March 15, 2008; 180(6): 4227 - 4234. [Abstract] [Full Text] [PDF] E. Terpos, O. Sezer, P. Croucher, and M.-A. Dimopoulos Myeloma bone disease and proteasome inhibition therapies Blood, August 15, 2007; 110(4): 1098 - 1104. [Abstract] [Full Text] [PDF] N. Giuliani, F. Morandi, S. Tagliaferri, M. Lazzaretti, S. Bonomini, M. Crugnola, C. Mancini, E. Martella, L. Ferrari, A. Tabilio, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients Blood, July 1, 2007; 110(1): 334 - 338. [Abstract] [Full Text] [PDF] T. Standal, N. Abildgaard, U.-M. Fagerli, B. Stordal, O. Hjertner, M. Borset, and A. Sundan HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma Blood, April 1, 2007; 109(7): 3024 - 3030. [Abstract] [Full Text] [PDF] S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie, and J. D. Shaughnessy Jr Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood, March 1, 2007; 109(5): 2106 - 2111. [Abstract] [Full Text] [PDF] N. Giuliani, V. Rizzoli, and G. D. Roodman Multiple myeloma bone disease: pathophysiology of osteoblast inhibition Blood, December 15, 2006; 108(13): 3992 - 3996. [Abstract] [Full Text] [PDF] G. D. Roodman New potential targets for treating myeloma bone disease. Clin. Cancer Res., October 15, 2006; 12(20): 6270s - 6273s. [Abstract] [Full Text] [PDF] R. N. Pearse Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling. Clin. Cancer Res., October 15, 2006; 12(20): 6274s - 6278s. [Abstract] [Full Text] [PDF] N. Giuliani, F. Morandi, S. Tagliaferri, S. Colla, S. Bonomini, G. Sammarelli, and V. Rizzoli Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients Blood, January 15, 2006; 107(2): 841 - 842. [Full Text] [PDF] T. Oshima, M. Abe, J. Asano, T. Hara, K. Kitazoe, E. Sekimoto, Y. Tanaka, H. Shibata, T. Hashimoto, S. Ozaki, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2 Blood, November 1, 2005; 106(9): 3160 - 3165. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020